← ANALYST RATINGS · TIPRANKS
United Therapeutics (UTHR): analyst forecast and price target
Analyst consensus
Moderate Buy10 Buy2 Hold1 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $653, the highest $728, the lowest $368. The average is +22.5% from the last price of $533.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $321 → $368+14.6% | Sell | −31.0% | Reiterated | 15.10.26on TipRanks 07:15 | 0.0%next day −0.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $620 → $622+0.3% | Buy | +16.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $623 → $622−0.2% | Buy | +16.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $618 → $622+0.6% | Buy | +16.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $620 → $625+0.8% | Buy | +17.2% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $631 → $633+0.3% | Buy | +18.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $645 → $638−1.1% | Buy | +19.7% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $725 | Buy | +36.0% | Reiterated | 13.10.26on TipRanks Oct 14 06:25 | −1.2%next day +0.5% | ↗ |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $685 | Buy | +28.5% | Reiterated | 12.10.26on TipRanks 07:35 | +0.2%next day −1.2% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $559 | Hold | +4.9% | Reiterated | 09.10.26on TipRanks 09:10 | +2.5%next day +0.2% · 5 days −1.0% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $687 → $710+3.3% | Buy | +33.2% | Reiterated | 08.10.26on TipRanks Oct 9 08:10 | −1.8%next day +2.5% · 5 days +1.9% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $677 → $708+4.6% | Buy | +32.8% | Reiterated | 08.10.26on TipRanks 09:05 | −1.8%next day +2.5% · 5 days +1.9% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $566 | Hold | +6.2% | Reiterated | 07.10.26on TipRanks 08:15 | +0.9%next day −1.8% · 5 days +0.1% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $704 | Buy | +32.1% | Reiterated | 01.10.26on TipRanks 10:25 | +5.3%next day −5.9% · 5 days −8.1% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $728 | Buy | +36.6% | Upgrade | 01.10.26on TipRanks 07:30 | +5.3%next day −5.9% · 5 days −8.1% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $700 | Buy | +31.3% | Initiated | 30.09.26on TipRanks Oct 1 07:08 | +12.8%next day +5.3% · 5 days −1.3% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $700 | Buy | +31.3% | Reiterated | 02.09.26on TipRanks 11:05 | −4.5%next day −1.4% · 5 days +3.4% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | $675 | Buy | +26.6% | Reiterated | 02.09.26on TipRanks 08:50 | −4.5%next day −1.4% · 5 days +3.4% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $660 | Buy | +23.8% | Reiterated | 06.08.26on TipRanks 15:05 | +2.8%next day +0.5% · 5 days −7.2% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $700 | Buy | +31.3% | Initiated | 09.04.26on TipRanks 20:13 | −0.5%next day +0.1% · 5 days −1.6% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $560 | Buy | +5.0% | Assigned | 03.03.26on TipRanks Mar 4 09:35 | −2.1%next day −2.4% · 5 days +7.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering United Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $639 at a price of $542 (+17.9%); now: $653 at $533 (+22.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 24 | 15 | 16 | 14 | 16 | 19 |
| Hold | 9 | 5 | 4 | 3 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 1 | 2 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $6.18 (from $4.40 to $7.26). Last quarter: $7.27.
Sales
Next quarter’s sales estimate — $785M (from $751M to $807M). Last quarter: $783M.
Best top-analyst consensus in the sector · Healthcare
About United Therapeutics
- CEO: Martine A. Rothblatt
- Employees: 1,400
- 1040 Spring Street, Silver Spring, MD, 20910, US
- www.unither.com
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag
Data from the stock’s TipRanks forecast page, read 14 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗